Artiva Biotherapeutics announced that it has launched and closed $78 million in Series A funding. This round of funding was co-led by 5AM Ventures, venBio Partners, and RA Capital Management. Additional investors include Medivate Partners and seed investors and strategic partners GC LabCell (Green Cross LabCell Corporation) and GC (Green Cross Holdings Corporation).

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva Biotherapeutics was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, our mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva's platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.